UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
SK Bioscience's shingles vaccine increases market share
Skyzoster, the first shingles vaccine domestically developed by SK Bioscien...
by Lee Han-soo
|
2019-05-22 17:04
라인
Handok, Sanofi to promote vaccines jointly
Handok said Wednesday that it has agreed with Sanofi Pasteur to co-promote ...
by Lee Han-soo
|
2019-05-22 15:48
라인
‘Dupixent is sole systemic, long-term treatment for atopic dermatitis’
Sanofi Genzyme is strengthening its position in the local atopic dermatitis...
by Lee Han-soo
|
2019-05-22 14:44
라인
Ministry grants additional indication to MSD’s immunotherapeutic drug
Keytruda, immunotherapy from MSD, has obtained additional approval from the...
by Lee Han-soo
|
2019-05-21 14:55
라인
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too?
Japan’s Health Ministry warned that Eli Lilly’s breast cancer therapy Verze...
by Kim Yun-mi
|
2019-05-21 14:19
라인
Roche’s breast cancer drug gains more insurance benefits
The Ministry of Health and Welfare has granted additional reimbursement to ...
by Lee Han-soo
|
2019-05-21 10:44
라인
Bridge Biotherapeutics releases first-in-human study for idiopathic pulmonary fibrosis treatment
Bridge Biotherapeutics announced that the company has presented interim dat...
by Lee Han-soo
|
2019-05-20 15:29
라인
Saxenda's sales surge 3,000 times yoy in Q1
Novo Nordisk’s Saxenda (ingredient: liraglutide), an obesity treatment, is ...
by Lee Han-soo
|
2019-05-17 14:37
라인
Daewoong launches Nabota in US amid controversy
Daewoong Pharmaceutical said it has officially launched Nabota, its botulin...
by Lee Han-soo
|
2019-05-16 16:33
라인
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride
The Korean Diabetes Association (KDA)’s revised guideline for diabetes trea...
by Kim Yun-mi
|
2019-05-15 15:30
라인
Keytruda wins nod as adjuvant therapy after melanoma surgery
The Ministry of Food and Drug Safety has approved PD-1 inhibitor immunother...
by Kim Yun-mi
|
2019-05-15 14:14
라인
EU lists Korea on drug standard whitelist
Korea's medical export to the European Union is expected to see strong ...
by Lee Han-soo
|
2019-05-15 13:25
라인
J&J's nasal spray depression treatment still met with some skepticism
Johnson & Johnson's Spravato (ingredient: esketamine), a new nasal spra...
by Lee Han-soo
|
2019-05-14 15:26
라인
‘MSD Korea’s foreign exec got drunk, sexually harassed female worker’
A foreign executive at MSD Korea not only sexually harassed a female employ...
by Jeong Sae-im
|
2019-05-14 11:53
라인
Korean companies excel multinational pharma’s R&D in investment-sales ratio
Local pharmaceutical companies surpassed multinational giants in research a...
by Lee Han-soo
|
2019-05-13 17:27
라인
Chinese patients vaccinate MSD’s product in Korea. Why?
An increasing number of Chinese female patients are visiting Korean obstetr...
by Lee Han-soo
|
2019-05-13 14:57
라인
US trade agency orders Daewoong to submit Nabota’s strain
The prolonged dispute between Medytox and Daewoong over the origin of Nabot...
by Lee Han-soo
|
2019-05-13 14:37
라인
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon
With Roche’s HER2-positive breast cancer drug Herceptin (trastuzumab) facin...
by Kim Yun-mi
|
2019-05-13 14:23
라인
Pfizer keeps lead over multinational pharmas in 2018 sales
Multinational pharmaceutical companies have shown mixed results in their sa...
by Lee Han-soo
|
2019-05-10 17:17
라인
Xeljianz is easier to use than biologic therapies -- is it safer, however?
Pfizer’s Xeljianz (tofacitinib), an oral Janus kinase (JAK) inhibitor to tr...
by Kim Yun-mi
|
2019-05-10 15:34
-
이전
41
42
43
44
45
46
47
48
49
50
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top